{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:29:06Z","timestamp":1792103346334,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Bloodstream infections caused by\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (PABSI) in hematological patients are associated with high morbidity and mortality. We investigated the epidemiology, risk factors, and outcomes of PABSI at our center.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All adult hematological patients with PABSI between January 2013 and July 2023 were included. Demographic and clinical characteristics, antimicrobial susceptibilities, antibiotic therapy, fluoroquinolone-prophylaxis, source of infection, and 30-day outcome were recorded. Descriptive statistics, tests for difference, and logistic regression models were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty patients with PABSI were identified with a median age of 58.5 years (range 24\u201378). 37 patients (74%) had severe neutropenia, 20 (40%) received allogeneic HSCT, and 29 (58%) had acute leukemia. A total of 34 (68%) had received timely appropriate anti-pseudomonal antibiotic therapy. The most common presumed cause of PABSI was mucositis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916, 32%), followed by pneumonia (8, 16%) and skin and soft tissue infections (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096, 12%). Empirical combination therapy was used in 16 (32%) patients, while targeted combination therapies were used in 27 (54%) patients.\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      detection led to treatment change in 31 (62%) cases. The overall 30-day survival rate was 78% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200939). Carbapenem-resistance occurred in 34% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917), and multidrug-resistance (MDR) in 20% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910). Prior antibiotic exposure was associated with resistance. Appropriate antibiotic therapy was associated with survival, whereas antibiotic resistance and organ infection were associated with a fatal outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prior antibiotic exposure in hematological patients is associated with resistance in PABSI, which is a major risk factor for a fatal outcome. Antibiotic stewardship efforts should be intensified and fluoroquinolone prophylaxis needs to be reconsidered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-024-02453-0","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T09:11:50Z","timestamp":1734599510000},"page":"1383-1392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Risk factors and outcome of Pseudomonas aeruginosa bloodstream infections (PABSI) in hematological patients: a single center retrospective cohort study"],"prefix":"10.1007","volume":"53","author":[{"given":"Johanna","family":"Kessel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Brunnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.G.T.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Scheich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hogardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"2453_CR1","doi-asserted-by":"publisher","unstructured":"Thaden JT, Park LP, Maskarinec SA, Ruffin F, Fowler VG, van Duin D. Results from a 13-Year prospective cohort study show increased Mortality Associated with Bloodstream infections caused by Pseudomonas aeruginosa compared to other Bacteria. Antimicrob Agents Chemother. May 2017;61(6). https:\/\/doi.org\/10.1128\/aac.02671-16.","DOI":"10.1128\/aac.02671-16"},{"key":"2453_CR2","doi-asserted-by":"publisher","unstructured":"Tofas P, et al. Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome. Diagn Microbiol Infect Dis. Aug. 2017;88(4):335\u201341. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.05.003.","DOI":"10.1016\/j.diagmicrobio.2017.05.003"},{"key":"2453_CR3","doi-asserted-by":"publisher","unstructured":"Scheich S, et al. Bloodstream infections with gram-negative organisms and the impact of multidrug resistance in patients with hematological malignancies. Ann Hematol. Nov. 2018;97(11):2225\u201334. https:\/\/doi.org\/10.1007\/s00277-018-3423-5.","DOI":"10.1007\/s00277-018-3423-5"},{"key":"2453_CR4","doi-asserted-by":"publisher","unstructured":"Heinz WJ et al. Nov., Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO), Ann. Hematol., vol. 96, no. 11, pp. 1775\u20131792, 2017, https:\/\/doi.org\/10.1007\/s00277-017-3098-3","DOI":"10.1007\/s00277-017-3098-3"},{"key":"2453_CR5","doi-asserted-by":"publisher","unstructured":"Inkster T, Walker J, Weinbren M. Waterborne infections in haemato-oncology units - a narrative review. J Hosp Infect. Aug. 2023;138:60\u201373. https:\/\/doi.org\/10.1016\/j.jhin.2023.05.011.","DOI":"10.1016\/j.jhin.2023.05.011"},{"key":"2453_CR6","doi-asserted-by":"publisher","unstructured":"Reynolds D, Kollef M. The epidemiology and Pathogenesis and treatment of Pseudomonas aeruginosa infections: an update. Drugs. Dec. 2021;81(18):2117\u201331. https:\/\/doi.org\/10.1007\/s40265-021-01635-6.","DOI":"10.1007\/s40265-021-01635-6"},{"key":"2453_CR7","unstructured":"Wilson MG, Pandey S. Pseudomonas aeruginosa, in StatPearls, Treasure Island (FL): StatPearls Publishing, 2024. Accessed: Jun. 21, 2024. [Online]. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557831\/"},{"key":"2453_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13756-018-0370-9","volume":"7","author":"G Raman","year":"2018","unstructured":"Raman G, Avendano EE, Chan J, Merchant S, Puzniak L. Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2018;7:79. https:\/\/doi.org\/10.1186\/s13756-018-0370-9.","journal-title":"Antimicrob Resist Infect Control"},{"key":"2453_CR9","doi-asserted-by":"publisher","unstructured":"Gudiol C et al. Mar., Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa, Antimicrob. Agents Chemother., vol. 64, no. 4, pp. e02494-19, 2020, https:\/\/doi.org\/10.1128\/AAC.02494-19","DOI":"10.1128\/AAC.02494-19"},{"key":"2453_CR10","doi-asserted-by":"publisher","unstructured":"Viasus D et al. Mar., Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection, Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis., vol. 26, no. 3, pp. 345\u2013350, 2020, https:\/\/doi.org\/10.1016\/j.cmi.2019.07.002","DOI":"10.1016\/j.cmi.2019.07.002"},{"key":"2453_CR11","doi-asserted-by":"publisher","unstructured":"Kim HS, et al. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study. BMC Infect Dis. Jul. 2017;17(1):500. https:\/\/doi.org\/10.1186\/s12879-017-2597-0.","DOI":"10.1186\/s12879-017-2597-0"},{"key":"2453_CR12","doi-asserted-by":"publisher","unstructured":"Zhao Y, et al. Risk factors and outcomes of antibiotic-resistant Pseudomonas aeruginosa Bloodstream infection in adult patients with Acute Leukemia. Clin Infect Dis off Publ Infect Dis Soc Am. Dec. 2020;71(4):S386\u201393. https:\/\/doi.org\/10.1093\/cid\/ciaa1522.","DOI":"10.1093\/cid\/ciaa1522"},{"key":"2453_CR13","doi-asserted-by":"publisher","unstructured":"Wang J et al. Oct., Adult acute leukemia patients with gram-negative bacteria bloodstream infection: Risk factors and outcomes of antibiotic-resistant bacteria, Ann. Hematol., vol. 103, no. 10, pp. 4021\u20134031, 2024, https:\/\/doi.org\/10.1007\/s00277-024-05866-x","DOI":"10.1007\/s00277-024-05866-x"},{"key":"2453_CR14","doi-asserted-by":"publisher","unstructured":"Scheich S, et al. Clinical impact of colonization with Multidrug-resistant organisms on outcome after autologous stem cell transplantation: a retrospective single-center study. Biol Blood Marrow Transpl. Sep. 2017;23(9):1455\u201362. https:\/\/doi.org\/10.1016\/j.bbmt.2017.05.016.","DOI":"10.1016\/j.bbmt.2017.05.016"},{"key":"2453_CR15","unstructured":"M100 Ed34| Performance Standards for Antimicrobial Susceptibility Testing. 34th Edition, Clinical & Laboratory Standards Institute. Accessed: Jul. 22, 2024. [Online]. Available: https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/"},{"key":"2453_CR16","unstructured":"eucast:. S, I and R definitions. Accessed: Jul. 17, 2024. [Online]. Available: https:\/\/www.eucast.org\/newsiandr"},{"key":"2453_CR17","doi-asserted-by":"publisher","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury, Nephron Clin. Pract., vol. 120, no. 4, pp. c179-184, 2012, https:\/\/doi.org\/10.1159\/000339789","DOI":"10.1159\/000339789"},{"key":"2453_CR18","doi-asserted-by":"publisher","unstructured":"Singer M, et al. The Third International Consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA. Feb. 2016;315(8):801\u201310. https:\/\/doi.org\/10.1001\/jama.2016.0287.","DOI":"10.1001\/jama.2016.0287"},{"key":"2453_CR19","doi-asserted-by":"publisher","unstructured":"Royo-Cebrecos C et al. Mar., Pseudomonas aeruginosa Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy, Microorganisms, vol. 12, no. 4, p. 705, 2024, https:\/\/doi.org\/10.3390\/microorganisms12040705","DOI":"10.3390\/microorganisms12040705"},{"key":"2453_CR20","doi-asserted-by":"publisher","unstructured":"Tumbarello M et al. Nov., Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality, Epidemiol. Infect., vol. 139, no. 11, pp. 1740\u20131749, 2011, https:\/\/doi.org\/10.1017\/S0950268810003055","DOI":"10.1017\/S0950268810003055"},{"key":"2453_CR21","doi-asserted-by":"publisher","first-page":"1156651","DOI":"10.3389\/fcimb.2023.1156651","volume":"13","author":"S Zhen","year":"2023","unstructured":"Zhen S, et al. Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa in patients with hematological diseases. Front Cell Infect Microbiol. 2023;13:1156651. https:\/\/doi.org\/10.3389\/fcimb.2023.1156651.","journal-title":"Front Cell Infect Microbiol"},{"key":"2453_CR22","doi-asserted-by":"publisher","unstructured":"Coppola PE et al. Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients, Microorganisms, vol. 8, no. 12, p. 2055, Dec. 2020, https:\/\/doi.org\/10.3390\/microorganisms8122055","DOI":"10.3390\/microorganisms8122055"},{"key":"2453_CR23","doi-asserted-by":"publisher","unstructured":"Royo-Cebrecos C et al. Sep., Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors, Pathogens, vol. 11, no. 10, p. 1132, 2022, https:\/\/doi.org\/10.3390\/pathogens11101132","DOI":"10.3390\/pathogens11101132"},{"key":"2453_CR24","doi-asserted-by":"publisher","unstructured":"Barron MA, Richardson K, Jeffres M, McCollister B. Risk factors and influence of carbapenem exposure on the development of carbapenem resistant Pseudomonas aeruginosa bloodstream infections and infections at sterile sites, SpringerPlus, vol. 5, no. 1, p. 755, 2016, https:\/\/doi.org\/10.1186\/s40064-016-2438-4","DOI":"10.1186\/s40064-016-2438-4"},{"key":"2453_CR25","doi-asserted-by":"publisher","unstructured":"Wong PHP, von Krosigk M, Roscoe DL, Lau TTY, Yousefi M, Bowie WR. Antimicrobial co-resistance patterns of gram-negative bacilli isolated from bloodstream infections: a longitudinal epidemiological study from 2002\u20132011. BMC Infect Dis. Oct. 2014;14:393. https:\/\/doi.org\/10.1186\/1471-2334-14-393.","DOI":"10.1186\/1471-2334-14-393"},{"key":"2453_CR26","doi-asserted-by":"publisher","unstructured":"Pang Z, Raudonis R, Glick BR, Lin T-J, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. Jan. 2019;37(1):177\u201392. https:\/\/doi.org\/10.1016\/j.biotechadv.2018.11.013.","DOI":"10.1016\/j.biotechadv.2018.11.013"},{"key":"2453_CR27","doi-asserted-by":"publisher","unstructured":"McMahon S, et al. Contribution of the oral and gastrointestinal microbiomes to Bloodstream infections in Leukemia patients. Microbiol Spectr. Jun. 2023;11(3):e0041523. https:\/\/doi.org\/10.1128\/spectrum.00415-23.","DOI":"10.1128\/spectrum.00415-23"},{"key":"2453_CR28","doi-asserted-by":"publisher","unstructured":"Weber S, et al. Profiling of bacterial bloodstream infections in hematological and oncological patients based on a comparative survival analysis. Ann Hematol. Jun. 2021;100(6):1593\u2013602. https:\/\/doi.org\/10.1007\/s00277-021-04541-9.","DOI":"10.1007\/s00277-021-04541-9"},{"key":"2453_CR29","doi-asserted-by":"publisher","unstructured":"Makhani SS et al. Nov., Inpatient Burden and Clinical Outcomes of Febrile Neutropenia in Cancer Patients: A National Inpatient Sample Database Analysis, Blood, vol. 140, no. Supplement 1, pp. 5154\u20135155, 2022, https:\/\/doi.org\/10.1182\/blood-2022-165527","DOI":"10.1182\/blood-2022-165527"},{"key":"2453_CR30","doi-asserted-by":"publisher","unstructured":"Paul M et al. Apr., European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine), Clin. Microbiol. Infect., vol. 28, no. 4, pp. 521\u2013547, 2022, https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025","DOI":"10.1016\/j.cmi.2021.11.025"},{"key":"2453_CR31","doi-asserted-by":"publisher","unstructured":"Pranita D, Tamma EL, Heil JA, Justo AJ, Mathers MJ, Satlin RA, Bonomo. Infectious Diseases Society of America 2024 Guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024;ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"2453_CR32","doi-asserted-by":"publisher","unstructured":"Christopeit M et al. Feb., Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO), Ann. Hematol., vol. 100, no. 2, pp. 321\u2013336, 2021, https:\/\/doi.org\/10.1007\/s00277-020-04297-8","DOI":"10.1007\/s00277-020-04297-8"},{"key":"2453_CR33","doi-asserted-by":"publisher","unstructured":"Aguilar-Guisado M, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (how long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol. Dec. 2017;4(12):e573\u201383. https:\/\/doi.org\/10.1016\/S2352-3026(17)30211-9.","DOI":"10.1016\/S2352-3026(17)30211-9"},{"key":"2453_CR34","doi-asserted-by":"publisher","unstructured":"Feng X et al. Mar., Is Short-Course Antibiotic Therapy Suitable for Pseudomonas aeruginosa Bloodstream Infections in Onco-hematology Patients With Febrile Neutropenia? Results of a Multi-institutional Analysis, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., vol. 78, no. 3, pp. 518\u2013525, 2024, https:\/\/doi.org\/10.1093\/cid\/ciad605","DOI":"10.1093\/cid\/ciad605"},{"key":"2453_CR35","doi-asserted-by":"publisher","unstructured":"Bucaneve G et al. Sep., Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia, N. Engl. J. Med., vol. 353, no. 10, pp. 977\u2013987, 2005, https:\/\/doi.org\/10.1056\/NEJMoa044097","DOI":"10.1056\/NEJMoa044097"},{"key":"2453_CR36","doi-asserted-by":"publisher","unstructured":"Cullen M et al. Sep., Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas, N. Engl. J. Med., vol. 353, no. 10, pp. 988\u2013998, 2005, https:\/\/doi.org\/10.1056\/NEJMoa050078","DOI":"10.1056\/NEJMoa050078"},{"key":"2453_CR37","doi-asserted-by":"publisher","unstructured":"Prabhu RM, Piper KE, Litzow MR, Steckelberg JM, Patel R. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis, Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol., vol. 24, no. 12, pp. 832\u2013838, Dec. 2005, https:\/\/doi.org\/10.1007\/s10096-005-0037-3","DOI":"10.1007\/s10096-005-0037-3"},{"key":"2453_CR38","doi-asserted-by":"publisher","unstructured":"Satlin MJ et al. Oct., Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., vol. 73, no. 7, pp. 1257\u20131265, 2021, https:\/\/doi.org\/10.1093\/cid\/ciab404","DOI":"10.1093\/cid\/ciab404"},{"key":"2453_CR39","doi-asserted-by":"publisher","unstructured":"Caldwell L, et al. Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology patients. Clin Infect Dis off Publ Infect Dis Soc Am. Jan. 2022;75(1):178\u20139. https:\/\/doi.org\/10.1093\/cid\/ciab1000.","DOI":"10.1093\/cid\/ciab1000"},{"key":"2453_CR40","doi-asserted-by":"publisher","unstructured":"Eryilmaz-Eren E, Izci F, Ture Z, Sagiroglu P, Kaynar L, Ulu-Kilic A, Bacteremia in Hematopoietic Stem Cell Recipients Receiving Fluoroquinolone Prophylaxis: Incidence, Resistance, and, Factors R. Infect. Chemother., vol. 54, no. 3, pp. 446\u2013455, Sep. 2022, https:\/\/doi.org\/10.3947\/ic.2022.0005","DOI":"10.3947\/ic.2022.0005"},{"key":"2453_CR41","doi-asserted-by":"publisher","unstructured":"Verlinden A et al. Oct., Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia, Eur. J. Haematol., vol. 93, no. 4, pp. 302\u2013308, 2014, https:\/\/doi.org\/10.1111\/ejh.12345","DOI":"10.1111\/ejh.12345"},{"key":"2453_CR42","doi-asserted-by":"publisher","unstructured":"Contejean A, et al. Antimicrobial stewardship in high-risk febrile neutropenia patients. Antimicrob Resist Infect Control. Mar. 2022;11(1):52. https:\/\/doi.org\/10.1186\/s13756-022-01084-0.","DOI":"10.1186\/s13756-022-01084-0"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02453-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02453-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02453-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:05:01Z","timestamp":1754352301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02453-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2453"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02453-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5212591\/v1","asserted-by":"object"}]},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"6 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}